FOXM1上调ELK1介导铁死亡促进宫颈癌细胞顺铂耐药性

陆美荣; 孙亮亮; 王彤

doi:10.11659/jjssx.03E024143

您当前的位置：

首页 >

文章列表页 >

FOXM1上调ELK1介导铁死亡促进宫颈癌细胞顺铂耐药性

基础研究 | 更新时间：2024-10-22

- FOXM1上调ELK1介导铁死亡促进宫颈癌细胞顺铂耐药性
- FOXM1 mediates ferroptosis and promotes cisplatin resistance in cervical cancer cells by up-regulating ELK1
- 局解手术学杂志 2024年33卷第10期页码：898-904
- 作者机构：
  
  1.西安国际医学中心医院妇科，陕西西安 710000
  2.榆林市第一医院药学部，陕西榆林 719000
- 作者简介：
  
  王彤，E-mail：117903681@qq.com
- 基金信息：
  
  陕西省重点研发计划项目(2023-YBSF-223)
- DOI：10.11659/jjssx.03E024143
  中图分类号： R737.3
- 纸质出版日期：2024-10-25，
  
  收稿日期：2024-03-26，
- 稿件说明：
移动端阅览
陆美荣,孙亮亮,王彤.FOXM1上调ELK1介导铁死亡促进宫颈癌细胞顺铂耐药性[J].局解手术学杂志,2024,33(10):898-904.

LU Mei-rong,SUN Liang-liang,WANG Tong.FOXM1 mediates ferroptosis and promotes cisplatin resistance in cervical cancer cells by up-regulating ELK1[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(10):898-904.
陆美荣,孙亮亮,王彤.FOXM1上调ELK1介导铁死亡促进宫颈癌细胞顺铂耐药性[J].局解手术学杂志,2024,33(10):898-904. DOI： 10.11659/jjssx.03E024143.

LU Mei-rong,SUN Liang-liang,WANG Tong.FOXM1 mediates ferroptosis and promotes cisplatin resistance in cervical cancer cells by up-regulating ELK1[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(10):898-904. DOI： 10.11659/jjssx.03E024143.

摘要

目的

探讨FOXM1通过ELK1对宫颈癌细胞顺铂（DDP）耐药性的影响及其潜在机制。

方法

生物信息学分析FOXM1和ELK1在宫颈癌组织中的表达；qPCR检测FOXM1和ELK1在宫颈癌细胞中的表达；双荧光素酶报告基因实验、ChIP实验验证二者结合情况。GSEA分析ELK1富集通路；

Pearson

相关性分析ELK1和抑制铁死亡关键基因的相关性。CCK-8检测细胞活力；PI染色及流式细胞术检测细胞凋亡情况。透射电镜观察线粒体形态变化；Lipid Peroxidation（MDA）Assay试剂盒检测丙二醛（MDA）含量；Werstern blot检测GPX4、SLC7A11、ACSL4蛋白表达。

结果

ELK1与FOXM1在宫颈癌组织和细胞中显著高表达，且二者存在结合位点。与oe-NC组相比，oe-ELK1组细胞存活率和IC

值显著提高；而与si-NC组相比，si-ELK1组细胞存活率和IC

值显著降低。与oe-NC+DMSO组相比，oe-ELK1+DMSO组线粒体没有出现萎缩、线粒体脊减少情况；而与oe-ELK1+DMSO组相比，oe-ELK1+erastin组线粒体出现了明显的萎缩、线粒体脊减少甚至消失现象。与oe-NC+DMSO组相比，oe-ELK1+DMSO组细胞内MDA含量显著降低，GPX4、SLC7A11蛋白表达增加，ACSL4蛋白表达降低，进一步用erastin处理则逆转了这一现象。与oe-NC+DMSO组相比，oe-ELK1+DMSO组CaSki/DDP细胞的IC

值显著提高，而erastin处理能够减弱这一促进作用。此外，与si-NC+oe-NC组相比，si-FOXM1+oe-NC组线粒体出现了明显的萎缩、线粒体脊减少甚至消失现象；而与si-FOXM1+oe-NC组相比，si-FOXM1+oe-ELK1组线粒体形态得到恢复。与si-NC+oe-NC组相比，si-FOXM1+oe-NC组细胞内MDA含量显著提高，GPX4、SLC7A11蛋白表达显著降低，ACSL4蛋白表达显著提高；而与si-FOXM1+oe-NC组相比，si-FOXM1+oe-ELK1组细胞内MDA含量显著降低，GPX4、SLC7A11蛋白表达显著提高，ACSL4蛋白表达显著降低。与si-NC+oe-NC组相比，si-FOXM1+oe-NC转染抑制了不同浓度DDP处理CaSki/DDP细胞的IC

值，而同时oe-ELK1转染能够逆转这一抑制作用。

结论

FOXM1通过上调ELK1的表达介导铁死亡，进而促进宫颈癌细胞DDP耐药。

Abstract

Objective

To investigate the effect and potential mechanism of FOXM1 on cisplatin （DDP）resistance in cervical cancer cells through ELK1.

Methods

The expressions of FOXM1 and ELK1 in

cervical cancer tissues were analyzed by bioinformatics. The expressions of FOXM1 and ELK1 in cervical cancer cells were detected by qPCR.Double luciferase reporter gene experiment and ChIP experiment were performed to verify the combination of the two. ELK1 enrichment pathway was analyzed by GSEA.The correlation between ELK1 and the key genes of inhibiting ferroptosis was analyzed by

Pearson

correlation analysis.Cell viability was detected by CCK-8， and cell apoptosis was detected by PI staining and flow cytometry. The morphological changes of mitochondria were observed by transmission electron microscopy. Lipid Peroxidation （MDA） Assay kit was used to detect the MDA content. The expressions of GPX4， SLC7A11 and ACSL4 were detected by Werstern blot.

Results

ELK1 and FOXM1 were highly expressed in cervical cancer tissues and cells， and and there were binding sites for them.Compared with the oe-NC group，the cell survival rate and IC

value of the oe-ELK1 group were significantly increased. Compared with the si-NC group， the cell survival rate and IC

value of the si-ELK1 group were significantly decreased. Compared with the oe-NC+DMSO group，mitochondrial atrophy and mitochondrial ridge reduction were not observed in the oe-ELK1+DMSO group.Compared with the oe-ELK1+DMSO group，it showed obvious mitochondriaatrophy， mitochondrial ridge reduction or even disappearance in the oe-ELK1+erastin group.Compared with the oe-NC+DMSO group，intracellular MDA content was significantly decreased，the expressions of GPX4 and SLC7A11 proteins were increased， and the expression of ACSL4 protein was decreased in the oe-ELK1+DMSO group.And the use of erastin had reversed the above phenomenon.Compared with the oe-NC+DMSO group， the IC

value of CaSki/DDP cells in the oe-ELK1+DMSO group was significantly increased，while the use of erastin had reduced the facilitation.In addition， compared with the si-NC+oe-NC group，the si-FOXM1+oe-NC group showed obvious

mitochondriaatrophy，mitochondrial ridge reduction or even disappearance. Compared with the si-FOXM1+oe-NC group， the mitochondrial morphology was restored in the si-FOXM1+oe-ELK1 group. Compared with the si-NC+oe-NC group，the intracellular MDA content in the si-FOXM1+oe-NC group was significantly increased， the expressions of GPX4 and SLC7A11 protein were decreased，and the expression of ACSL4 protein was increased.Compared with the si-FOXM1+oe-NC group， the intracellular MDA contentin the si-FOXM1+oe-ELK1 group was significantly decreased，and the expressions of GPX4 and SLC7A11 protein were increased，while the expression of ACSL4 protein was decreased.Compared with the si-NC+oe-NC group，the IC

value of CaSki/DDP cells in the si-FOXM1+oe-NC group was significantly decreased.Meanwhile，oe-ELK1 transfection has reversed the inhibition effect.

Conclusion

FOXM1 can mediate ferroptosis by up-regulating the expression of ELK1， thus promoting DDP resistance in cervical cancer cells.

关键词

FOXM1ELK1宫颈癌铁死亡顺铂耐药

Keywords

FOXM1ELK1cervical cancerferroptosiscisplatin resistance

references

Kumar L，Harish P，Malik PS，et al.Chemotherapy and targeted therapy in the management of cervical cancer［J］.Curr Probl Cancer，2018，42（2）：120-128.doi：10.1016/j.currproblcancer.2018. 01.016http://dx.doi.org/10.1016/j.currproblcancer.2018.01.016.

Gennigens C，Jerusalem G，Lapaille L，et al.Recurrent or primary metastatic cervical cancer：current and future treatments ［J］.ESMO Open，2022，7（5）：100579.doi：10.1016/j.esmoop.2022.100579http://dx.doi.org/10.1016/j.esmoop.2022.100579.

Chang X，Miao J.Ferroptosis：mechanism and potential applications in cervical cancer ［J］.Front Mol Biosci，2023，10：1164398.doi：10.3389/fmolb.2023.1164398http://dx.doi.org/10.3389/fmolb.2023.1164398.

Jiang M，Song Y，Liu H，et al.DHODH inhibition exerts synergistic therapeutic effect with cisplatin to induce ferroptosis in cervical cancer through regulating mTOR pathway ［J］.Cancers （Basel），2023，15（2）：546.doi：10.3390/cancers15020546http://dx.doi.org/10.3390/cancers15020546.

Zhang Z，Hu Q，Ye S，et al.Inhibition of the PIN1-NRF2/GPX4 axis imparts sensitivity to cisplatin in cervical cancer cells ［J］.Acta Biochim Biophys Sin （Shanghai），2022，54（9）：1325-1335.doi：10.3724/abbs.2022109http://dx.doi.org/10.3724/abbs.2022109.

Wei S，Yu Z，Shi R，et al.GPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1［J］.BMC Cancer，2022，22（1）：881.doi：10.1186/s12885-022-09986-3http://dx.doi.org/10.1186/s12885-022-09986-3.

He GN，Bao NR，Wang S，et al.Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4 ［J］.Drug Des Devel Ther，2021，15：3965-3978.doi：10.2147/DDDT.S332847http://dx.doi.org/10.2147/DDDT.S332847.

毛万丽，李杰慧，冉立.宫颈癌顺铂耐药研究进展［J］.现代肿瘤医学，2021，29（16）：6.doi：10.3969/j.issn.1672-4992 2021. 16.036http://dx.doi.org/10.3969/j.issn.1672-49922021.16.036.

Tong X，Tang R，Xiao M，et al.Targeting cell death pathways for cancer therapy：recent developments in necroptosis，pyroptosis，ferroptosis，and cuproptosis research ［J］.J Hematol Oncol，2022，15（1）：174.doi：10.1186/s13045-022-01392-3http://dx.doi.org/10.1186/s13045-022-01392-3.

王睿，沙仁高娃.顺铂诱导铁死亡促进肿瘤相关巨噬细胞极化抑制宫颈癌细胞耐药性［J］.现代肿瘤医学，2022，30（13）：2320-2325.doi：10.3969 /j.issn.1672-4992.2022.13.005http://dx.doi.org/10.3969/j.issn.1672-4992.2022.13.005.

赵元莘，翟岩辉，师粒晶，等.Ets转录因子ELK1功能及其作用机制的研究进展［J］.中国生物制品学杂志，2023，36（5）：614-618.doi：10.13200/j.cnki.cjb.003891http://dx.doi.org/10.13200/j.cnki.cjb.003891.

Li K，Liu Y，Ding Y，et al.BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer［J］.J Clin Invest，2022，132（22）：e161308.doi：10.1172/JCI161308http://dx.doi.org/10.1172/JCI161308.

Ahmad A，Zhang W，Wu M，et al.Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes［J］.Genes Genomics，2018，40（3）：243-251.doi：10.1007/s13258-017-0624-6http://dx.doi.org/10.1007/s13258-017-0624-6.

Li P，Shi Y，Gao D，et al.ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner［J］.Int J Biol Sci，2022，18（16）：6145-6162.doi：10.7150/ijbs.75063http://dx.doi.org/10.7150/ijbs.75063.

Huang Y，Luo F.Elevated microRNA-130b-5p or silenced ELK1 inhibits self-renewal ability，proliferation，migration，and invasion abilities，and promotes apoptosis of cervical cancer stem cells［J］.IUBMB Life，2021，73（1）：118-129.doi：10.1002/iub.2409http://dx.doi.org/10.1002/iub.2409.

Rodriguez-Aguayo C，Bayraktar E，Ivan C，et al.PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis［J］.EBioMedicine，2022，83：104194.doi：10.1016/j.ebiom.2022. 104194http://dx.doi.org/10.1016/j.ebiom.2022.104194.

Yan J，Gao Y，Lin S，et al.EGR1-CCL2 feedback loop maintains epithelial-mesenchymal transition of cisplatin-resistant gastric cancer cells and promotes tumor angiogenesis［J］.Dig Dis Sci，2022，67（8）：3702-3713.doi：10.1007/s10620-021-07250-5http://dx.doi.org/10.1007/s10620-021-07250-5.

Dun S，Gao L.Tanshinone I attenuates proliferation and chemoresistance of cervical cancer in a KRAS-dependent manner［J］.J Biochem Mol Toxicol，2019，33（4）：e22267.doi：10.1002/jbt.22267http://dx.doi.org/10.1002/jbt.22267.

Koo CY，Muir KW，Lam EW.FOXM1：from cancer initiation to progression and treatment ［J］.Biochim Biophys Acta，2012，1819（1）：28-37.doi：10.1016/j.bbagrm.2011.09.004http://dx.doi.org/10.1016/j.bbagrm.2011.09.004.

Zhu Z，Zhou Y，Chen Y，et al.m（6）A methyltransferase KIAA1429 regulates the cisplatin sensitivity of gastric cancer cells via stabilizing FOXM1 mRNA［J］.Cancers （Basel），2022，14（20）：5025.doi：10.3390/cancers14205025http://dx.doi.org/10.3390/cancers14205025.

Jiang J，Zhu J，Qiu P，et al.HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2 ［J］.Funct Integr Genomics，2023，24（1）：3.doi：10.1007/s10142-023-01279-7http://dx.doi.org/10.1007/s10142-023-01279-7.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

长链非编码RNA SATB2-AS1抑制肺腺癌进展的机制研究

SKA2对宫颈癌细胞增殖、迁移和侵袭的影响及其预后价值

miR-30d-5p对宫颈癌细胞生长和转移的影响

精准膜解剖下保留盆腔自主神经宫颈癌根治术疗效观察

hsa_circ_0011946靶向miR-767-3p调控宫颈癌细胞增殖、迁移和侵袭